The Pyelonephritis drugs in development market research report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Pyelonephritis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued products.

GlobalData tracks 22 drugs in development for Pyelonephritis by 23 companies/universities/institutes. The top development phase for Pyelonephritis is phase iii with nine drugs in that stage. The Pyelonephritis pipeline has 22 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Pyelonephritis pipeline products market are: Pfizer, Wockhardt and Qilu Pharmaceutical.

The key targets in the Pyelonephritis pipeline products market include Beta Lactamase (EC, Penicillin Binding Protein (PBP), and Penicillin Binding Protein 3 (PBP3).

The key mechanisms of action in the Pyelonephritis pipeline product include Beta Lactamase (EC Inhibitor with nine drugs in Pre-Registration. The Pyelonephritis pipeline products include five routes of administration with the top ROA being Intravenous and one key molecule types in the Pyelonephritis pipeline products market including Small Molecule.

Pyelonephritis overview

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in the urethra or bladder and travels up into the kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion, and back or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract, and damage to nerves around the bladder. Treatment includes antibiotics.

For a complete picture of Pyelonephritis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.